Endogenous maternal serum preimplantation factor levels in earlyonset preeclamptic pregnancies

N.A.

Makale detayları

Endogenous maternal serum preimplantation factor levels in earlyonset preeclamptic pregnancies

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Clinical Sciences

Dergi:

Marmara Medical Journal Vol.36 Issue 2, pp.203-209

Belge Tipi:

Makale

Yayın Tarihi:

5/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001289743

pISSN:

1019-1941

Anahtar kelimeler:

Özet:

 Objective: Preimplantation-factor PIF is a new peptide with many potential functions. We aimed to compare the maternal serum PIF levels among early-onset preeclamptic patients with the healthy controls at the same gestational age. Patients and Methods: Thirty-nine early-onset preeclamptic  34 gestational weeks patients and 45 healthy expecting women have been added to our study. Patients with or suspicion of any chronical maternal disease, gestational diabetes, twin pregnancies, fetal or placental anomalies or any other obstetric complications have been excluded. Competitive enzyme-linked immunosorbent assay ELISA Elabscience Biotechnology Co., Texas, USA has been used to analyze the PIF levels in the collected samples. Gestational age, maternal age, gravida, parity, fetal growth, body mass index BMI, maternal weight and height, plasma PIF levels have been collectedmeasured and analyzed in both groups. Results: The primary outcome of our study the Preimplantation Factor- was significantly higher in study group than the healthy controls 100.36  41.92 vs. 83.14  51.27 p0.016. Conclusions: We have found the PF levels statistically higher in the study group. PIF levels might have a role in the progression and pathogenesis of the preeclamptic patients. Further studies with larger groups have to be planned and performed to resolve the real relation between PIF and preeclampsia.

 Objective: Preimplantation-factor PIF is a new peptide with many potential functions. We aimed to compare the maternal serum PIF levels among early-onset preeclamptic patients with the healthy controls at the same gestational age. Patients and Methods: Thirty-nine early-onset preeclamptic  34 gestational weeks patients and 45 healthy expecting women have been added to our study. Patients with or suspicion of any chronical maternal disease, gestational diabetes, twin pregnancies, fetal or placental anomalies or any other obstetric complications have been excluded. Competitive enzyme-linked immunosorbent assay ELISA Elabscience Biotechnology Co., Texas, USA has been used to analyze the PIF levels in the collected samples. Gestational age, maternal age, gravida, parity, fetal growth, body mass index BMI, maternal weight and height, plasma PIF levels have been collectedmeasured and analyzed in both groups. Results: The primary outcome of our study the Preimplantation Factor- was significantly higher in study group than the healthy controls 100.36  41.92 vs. 83.14  51.27 p0.016. Conclusions: We have found the PF levels statistically higher in the study group. PIF levels might have a role in the progression and pathogenesis of the preeclamptic patients. Further studies with larger groups have to be planned and performed to resolve the real relation between PIF and preeclampsia.

 Objective: Preimplantation-factor PIF is a new peptide with many potential functions. We aimed to compare the maternal serum PIF levels among early-onset preeclamptic patients with the healthy controls at the same gestational age. Patients and Methods: Thirty-nine early-onset preeclamptic  34 gestational weeks patients and 45 healthy expecting women have been added to our study. Patients with or suspicion of any chronical maternal disease, gestational diabetes, twin pregnancies, fetal or placental anomalies or any other obstetric complications have been excluded. Competitive enzyme-linked immunosorbent assay ELISA Elabscience Biotechnology Co., Texas, USA has been used to analyze the PIF levels in the collected samples. Gestational age, maternal age, gravida, parity, fetal growth, body mass index BMI, maternal weight and height, plasma PIF levels have been collectedmeasured and analyzed in both groups. Results: The primary outcome of our study the Preimplantation Factor- was significantly higher in study group than the healthy controls 100.36  41.92 vs. 83.14  51.27 p0.016. Conclusions: We have found the PF levels statistically higher in the study group. PIF levels might have a role in the progression and pathogenesis of the preeclamptic patients. Further studies with larger groups have to be planned and performed to resolve the real relation between PIF and preeclampsia.

 Objective: Preimplantation-factor PIF is a new peptide with many potential functions. We aimed to compare the maternal serum PIF levels among early-onset preeclamptic patients with the healthy controls at the same gestational age. Patients and Methods: Thirty-nine early-onset preeclamptic  34 gestational weeks patients and 45 healthy expecting women have been added to our study. Patients with or suspicion of any chronical maternal disease, gestational diabetes, twin pregnancies, fetal or placental anomalies or any other obstetric complications have been excluded. Competitive enzyme-linked immunosorbent assay ELISA Elabscience Biotechnology Co., Texas, USA has been used to analyze the PIF levels in the collected samples. Gestational age, maternal age, gravida, parity, fetal growth, body mass index BMI, maternal weight and height, plasma PIF levels have been collectedmeasured and analyzed in both groups. Results: The primary outcome of our study the Preimplantation Factor- was significantly higher in study group than the healthy controls 100.36  41.92 vs. 83.14  51.27 p0.016. Conclusions: We have found the PF levels statistically higher in the study group. PIF levels might have a role in the progression and pathogenesis of the preeclamptic patients. Further studies with larger groups have to be planned and performed to resolve the real relation between PIF and preeclampsia.

Makale detayları

Endogenous maternal serum preimplantation factor levels in earlyonset preeclamptic pregnancies

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Clinical Sciences

Dergi:

Marmara Medical Journal Vol.36 Issue 2, pp.203-209

Belge Tipi:

Makale

Yayın Tarihi:

5/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001289743

pISSN:

1019-1941

Preimplantation Factor

Preeclampsia

Maternal SerumPreimplantation Factor

Preeclampsia

Maternal Serum

Sayı

Makale detayları

Endogenous maternal serum preimplantation factor levels in earlyonset preeclamptic pregnancies

Yazarlar: N.A.

Yayıncı: Marmara University

Ana Başlıklar: Clinical Sciences

Dergi: Marmara Medical Journal Vol.36 Issue 2, pp.203-209

Belge Tipi: Makale

Yayın Tarihi: 5/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001289743

pISSN: 1019-1941

Preimplantation Factor

Preeclampsia

Maternal SerumPreimplantation Factor

Preeclampsia

Maternal Serum

Sayı

Yazarlar:

N.A.

Yayıncı:

Marmara University

Ana Başlıklar:

Clinical Sciences

Dergi:

Marmara Medical Journal Vol.36 Issue 2, pp.203-209

Belge Tipi:

Makale

Yayın Tarihi:

5/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001289743

pISSN:

1019-1941